ACT Brief: RWD Integration Accelerates, FDA Advances Ultra-Rare Therapies, and Collaboration Shapes the Next Decade

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new episode of the Applied Clinical Trials Podcast, C.K. Wang, MD, chief medical officer at COTA, and Sujay Jadhav, CEO of Verana Health, discuss how their merger is transforming real-world data from a retrospective tool into a prospective driver of trial design and execution. With access to 95 million patient records and 25,000 providers, they explain how machine learning is improving patient identification, trial feasibility, and regulatory-grade evidence generation, with implications for rare disease and pediatric research.
• The FDA has issued draft guidance introducing the Plausible Mechanism Framework to support individualized therapies for ultra-rare diseases. The approach allows sponsors to demonstrate effectiveness using mechanism-based evidence when conventional trials aren’t feasible. FDA leaders highlight regulatory flexibility and streamlined pathways while maintaining scientific rigor for therapies targeting specific genetic, cellular, or molecular abnormalities.
• A decade of collaboration at TransCelerate BioPharma Inc. shows how shared problem-solving can reshape clinical development. In an op-ed on Pharmaceutical Executive, founding member Andy Lee and CEO Janice Chang emphasize aligning on common processes, standardizing data structures, and fostering a culture that absorbs change. These practices have enabled more patient-centric trial designs, smoother operations, and faster adaptation to emerging challenges across the industry.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.